The Boston Scientific Corporation (NYSE:BSX) post approval clinical trial on bronchial thermoplasty (BT) has shown positive results. The Severe Persistent Asthma (PAS2) study was evaluating responses of patients treated with the Alair System from which the results demonstrated reduced complications in adult patients. The PAS2 open-label study enrolled 284 patients who suffered from asthma that was not well managed by inhaled corticosteroids (ICS).

The overall outcome of the study was remarkable clinical improvement

The participants of the study were 45.7 years and above with a body mass index of 32.2 kg/m2. Having received treatment for two years there was a notable decreased of severe asthma exacerbation attacks from 77.8% to 50.4% within the first year. Asthma-related hospitalizations also diminished from 16.1% to 8% followed by 7.3% in year two.

Commending the results, principal investigator and director, Geoffrey Chupp stated, “The findings of the PAS2 study provide important real-world evidence that patients with poorly controlled severe asthma on high doses of medications experience significant and sustained improvements in asthma control following BT.”

Bronchial Thermoplasty can transform the lives of people with severe asthma

Records have it that close to 25 million people are asthma sufferers with about 10% of them being severe. A majority of the severe cases are life threatening and sometimes may not be alleviated even with the highest dose of standard medications.

However, senior VP and president, Endoscopy, Boston Scientific, Art Butcher says that Bronchial Thermoplasty has the capability of soothing these conditions. Their severity and frequency vary from one person to another but the being a global medical technology leader, the company is willing to put all its efforts into transforming people’s lives. It has had significant market presence for over 35 years and its interests in addressing unmet patient needs are well outlined

The Alair System for BT is the first non-pharmacologic device-based treatment to have been approved by the U.S. Food and Drug Administration in 2010. It delivers managed thermal energy into the airway wall to decrease the quantity of overloaded smooth muscle tissue. In the meantime, Boston Scientific’s stock was trading at $27.05 witnessing an increase of $0.38 or 1.42%.